NSCLC has one of the most dynamic drug development pipelines in oncology, including multiple targeted and biomarker-driven therapies. DRG expects the NSCLC therapy market to experience robust…
In recent years therapeutic options for ovarian cancer have increased. Prior to 2016, the only targeted therapy approved for the indication was AstraZeneca’s Lynparza. However, the treatment…
Biomarker-targeted therapies are distinguished from other oncology drugs in that they are accompanied by a diagnostic test that can identify a specific patient type most likely to benefit from…
Market Outlook The expedited approvals of Novartis’s Kymriah for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute lymphocytic leukemia (ALL), and…
Breast cancer affects thousands of individuals in Brazil and Mexico, and is managed with premium-priced agents, chemotherapy, and hormone therapy. In Mexico, coverage of treatment varies across the…
The increase in oral oncolytics has fueled an increase in oncologist dispensing of drugs either from the physician office or from a pharmacy owned by the practice or hospital, as allowed by state…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
DRG Epidemiology's coverage of small-cell lung cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence…
The treatment of both solid and hematological cancers is associated with a wide range of serious side effects, including chemotherapy-associated neutropenia and anemia, nausea and vomiting, and…
Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…
Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to treatment journey. The quantitative sequencing analysis…